Skin cancer treatment for head and neck
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a combination of an immunotherapy drug (cemiplimab) and a special kind of radiation for a type of skin cancer called cutaneous squamous cell carcinoma. It is designed for people whose cancer has come back or is hard to treat with standard surgery or radiation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your skin cancer is in the head or neck area and is locally advanced or has spread to nearby lymph nodes.
- You have not had chemotherapy, targeted therapy, or immunotherapy before.
- You are not able to have standard surgery or radiation because of health problems, frailty, or age (over 70).
- You have at least one tumor that can be measured.
- You have a tissue sample (biopsy) available for testing, preferably from a lymph node.
- Your blood counts and organ function need to be within a certain range.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two immunotherapy drugs (cemiplimab and fianlimab) combined with standard chemotherapy and radiation for people with advanced head and neck cancer that cannot be removed by surgery. The goal is to see if this combination can improve outcomes by helping the immune system attack the cancer.
This trial tests a focused radiation treatment after surgery for people with a common skin cancer (squamous cell carcinoma) that has spread to the lymph nodes in the neck or near the ear. The goal is to see if this approach can prevent the cancer from coming back.
This Phase 1 trial tests cemiplimab (an immune system medicine) given with “induction” chemotherapy before the main treatment for locally advanced squamous cell head and neck cancer. It’s designed to see how well this treatment is tolerated and to learn about immune responses that may help future patients.
This Phase 1 trial tests how well cemiplimab (an immune treatment) can work when combined with chemotherapy and an additional immunotherapy for certain head and neck cancers. It may help shrink the cancer and improve outcomes, while also checking safety and dosing.
This trial combines immunotherapy with a special type of radiation that spares healthy lymph nodes, aiming to boost the body's immune response against the tumor. It is for patients with certain types of head and neck cancer that have not spread too far and can be surgically removed.
This trial tests a combination of two targeted drugs (an immunotherapy and an EGFR inhibitor) given before surgery to shrink locally advanced skin cancer and potentially make surgery easier or more successful. It may help people whose skin cancer is hard to treat with surgery alone.
Hear when a new Cutaneous Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.